Skip to Main Content
BLACK FRIDAY SALE

60% off Quiver Premium for new subscribers

...

Use Promo Code:

BLACKFRIDAY26
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Why Revolution Medicines (RVMD) Stock Is Up Today

None

Revolution Medicines (RVMD) is up 4.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is fresh positive clinical data for RASONQUE in first-line metastatic pancreatic cancer, released on November 19, 2026, which reinforced investor optimism around the drug’s growth potential. The move also appears supported by the company’s recent European Union approval for RASONQUE and by strong early commercial traction following its U.S. launch.

Details:

  • Revolution Medicines announced updated Phase 1/2 data for RASONQUE plus gemcitabine and nab-paclitaxel, showing a 60.7% confirmed objective response rate and a 90.2% disease control rate in first-line metastatic pancreatic cancer.
  • The same update showed median progression-free survival of 12.8 months and estimated 12-month overall survival of 76.6%, results that support the ongoing Phase 3 RASolute 303 study.
  • On November 16, 2026, the company said the European Commission approved RASONQUE for previously treated metastatic pancreatic cancer, expanding the addressable market beyond the United States.
  • Earlier this month, Revolution Medicines reported $198 million in partial-quarter net product revenue for RASONQUE after the August U.S. approval, highlighting unusually strong launch momentum.
  • Sources:

    Revolution Medicines, FDA, SEC

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $RVMD Insider Trading Activity

    RVMD Insider Trades

    $RVMD insiders have traded $RVMD stock on the open market 124 times in the past 6 months. Of those trades, 0 have been purchases and 124 have been sales.

    Here’s a breakdown of recent trading of $RVMD stock by insiders over the last 6 months:

    • STEPHEN MICHAEL KELSEY (See Remarks) has made 0 purchases and 17 sales selling 129,435 shares for an estimated $25,045,328.
    • MARK A GOLDSMITH (See Remarks) has made 0 purchases and 21 sales selling 110,008 shares for an estimated $22,342,355.
    • MARGARET A HORN (Chief Operating Officer) has made 0 purchases and 11 sales selling 104,967 shares for an estimated $16,883,735.
    • LORENCE H. KIM has made 0 purchases and 14 sales selling 73,090 shares for an estimated $14,967,124.
    • JEFF CISLINI (SVP & General Counsel) has made 0 purchases and 10 sales selling 63,182 shares for an estimated $13,070,226.
    • JACK ANDERS (Chief Financial Officer) has made 0 purchases and 14 sales selling 42,525 shares for an estimated $7,957,157.
    • ANTHONY MANCINI (See Remarks) has made 0 purchases and 16 sales selling 33,551 shares for an estimated $6,393,191.
    • ELIZABETH M ANDERSON has made 0 purchases and 5 sales selling 10,143 shares for an estimated $1,958,015.
    • ALAN B. SANDLER (Chief Development Officer) has made 0 purchases and 7 sales selling 6,650 shares for an estimated $1,343,234.
    • SUSHIL PATEL has made 0 purchases and 9 sales selling 5,580 shares for an estimated $1,048,967.

    To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

    $RVMD Hedge Fund Activity

    We have seen 477 institutional investors add shares of $RVMD stock to their portfolio, and 307 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

    $RVMD Analyst Ratings

    Wall Street analysts have issued reports on $RVMD in the last several months. We have seen 17 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

    Here are some recent analyst ratings:

    • HC Wainwright & Co. issued a "Buy" rating on 11/17/2026
    • Morgan Stanley issued a "Overweight" rating on 11/13/2026
    • TD Cowen issued a "Buy" rating on 11/05/2026
    • RBC Capital issued a "Outperform" rating on 11/05/2026
    • Piper Sandler issued a "Overweight" rating on 11/05/2026
    • Truist Securities issued a "Buy" rating on 11/05/2026
    • Guggenheim issued a "Buy" rating on 11/05/2026

    To track analyst ratings and price targets for $RVMD, check out Quiver Quantitative's $RVMD forecast page.

    $RVMD Price Targets

    Multiple analysts have issued price targets for $RVMD recently. We have seen 19 analysts offer price targets for $RVMD in the last 6 months, with a median target of $265.0.

    Here are some recent targets:

    • Robert Burns from HC Wainwright & Co. set a target price of $350.0 on 11/17/2026
    • Sean Laaman from Morgan Stanley set a target price of $247.0 on 11/13/2026
    • Tyler Van Buren from TD Cowen set a target price of $270.0 on 11/05/2026
    • Leonid Timashev from RBC Capital set a target price of $321.0 on 11/05/2026
    • Kelsey Goodwin from Piper Sandler set a target price of $222.0 on 11/05/2026
    • Gregory Renza from Truist Securities set a target price of $261.0 on 11/05/2026
    • Michael Schmitz from Guggenheim set a target price of $298.0 on 11/05/2026

    This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.

    Add Quiver Quantitative to your preferred sources on Google Google News Logo

    Suggested Articles